As it waits patiently for US approval for Bimzelx in psoriasis, UCB S.A. has given an insight into the European launch of the potential autoimmune disease blockbuster which has started fairly slowly.
During its full-year results presentation, the Belgian drugmaker noted that Bimzelx (bimekizumab), its dual interleukin-17A and IL-17F inhibitor which has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?